Abstract
With the exception of viral-induced malignances such as cervical cancer, high-affinity proinflammatory T cells specific for tumor-associated antigens (TAA) are either deleted or rendered anergic as a consequence of central and peripheral tolerance. Reprogramming of peripheral blood-derived T cells while preserving their full functional potential to recognize and kill tumor cells is thus required to circumvent negative selection processes. One tactic for redirecting specificity is through genetic modification of T cells to express a chimeric antigen receptor (CAR) targeting a TAA such as CD19, which is expressed on B-lineage malignancies, and their subsequent adoptive transfer into cancer patients. Transposon-based gene transfer is an alternative method to retroviral transduction for integrating such transgenes into the T-cell genome. The Sleeping Beauty (SB) transposon system is a safe and low-cost technique for engineering T cells to express a CD19-specific CAR from a plasmid. This gene-transfer approach provides sufficient transgene integration for retrieval of clinically sufficient numbers of CAR+ T cells for clinical translation into the first-in-human clinical trial already enrolling patients.
Keywords: Cancer, DNA transposons, gene therapy, T cells, transposition, Sleeping Beauty
Current Drug Therapy
Title:Transposon-Based Engineering of Clinical-Grade T Cells for Cancer Therapy
Volume: 7 Issue: 1
Author(s): Kirsten Switzer, Brian Rabinovich and Laurence J.N. Cooper
Affiliation:
Keywords: Cancer, DNA transposons, gene therapy, T cells, transposition, Sleeping Beauty
Abstract: With the exception of viral-induced malignances such as cervical cancer, high-affinity proinflammatory T cells specific for tumor-associated antigens (TAA) are either deleted or rendered anergic as a consequence of central and peripheral tolerance. Reprogramming of peripheral blood-derived T cells while preserving their full functional potential to recognize and kill tumor cells is thus required to circumvent negative selection processes. One tactic for redirecting specificity is through genetic modification of T cells to express a chimeric antigen receptor (CAR) targeting a TAA such as CD19, which is expressed on B-lineage malignancies, and their subsequent adoptive transfer into cancer patients. Transposon-based gene transfer is an alternative method to retroviral transduction for integrating such transgenes into the T-cell genome. The Sleeping Beauty (SB) transposon system is a safe and low-cost technique for engineering T cells to express a CD19-specific CAR from a plasmid. This gene-transfer approach provides sufficient transgene integration for retrieval of clinically sufficient numbers of CAR+ T cells for clinical translation into the first-in-human clinical trial already enrolling patients.
Export Options
About this article
Cite this article as:
Switzer Kirsten, Rabinovich Brian and J.N. Cooper Laurence, Transposon-Based Engineering of Clinical-Grade T Cells for Cancer Therapy, Current Drug Therapy 2012; 7 (1) . https://dx.doi.org/10.2174/157488512800389155
DOI https://dx.doi.org/10.2174/157488512800389155 |
Print ISSN 1574-8855 |
Publisher Name Bentham Science Publisher |
Online ISSN 2212-3903 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Cell Arrest and Apoptosis Induced by the Next Generation of Vanadium Based Drugs: Action Mechanism to Structure Relation and Future Perspectives
Anti-Cancer Agents in Medicinal Chemistry Histone Lysine-Specific Methyltransferases and Demethylases in Carcinogenesis: New Targets for Cancer Therapy and Prevention
Current Cancer Drug Targets Cytokines and Hormones in the Regulation of Hypoxia Inducible Factor-1α (HIF-1α)
Cardiovascular & Hematological Agents in Medicinal Chemistry Lycopene: A Review of Its Potential as an Anticancer Agent
Current Medicinal Chemistry - Anti-Cancer Agents Rediscovering the Antibiotics of the Hive
Recent Patents on Anti-Infective Drug Discovery Signal Transduction and Heavy Ion Radiation Therapy: Biological Mechanisms, Biological Quality Assurance, and New Multimodality Approach
Current Signal Transduction Therapy The Yin and Yang of Non-Neuronal α7-Nicotinic Receptors in Inflammation and Autoimmunity
Current Drug Targets Mechanisms of Action and Chemical-Biological Interactions Between Ozone and Body Compartments: A Critical Appraisal of the Different Administration Routes
Current Drug Therapy Prospects of Gene Therapy for Pulmonary Diseases: Progress and Limitations
Medicinal Chemistry Porphyrins in Photodynamic Therapy - A Search for Ideal Photosensitizers
Current Medicinal Chemistry - Anti-Cancer Agents Lesson Learned from Nature for the Development of Novel Anti-Cancer Agents: Implication of Isoflavone, Curcumin, and their Synthetic Analogs
Current Pharmaceutical Design Expression of Defensins in Gingiva and Their Role in Periodontal Health and Disease
Current Pharmaceutical Design Perspectives for Novel Mixed Diruthenium-Organic Drugs as Metallopharmaceuticals in Cancer Therapy
Anti-Cancer Agents in Medicinal Chemistry Notch Signaling Proteins: Legitimate Targets for Cancer Therapy
Current Protein & Peptide Science An Update on Overcoming MDR1-Mediated Multidrug Resistance in Cancer Chemotherapy
Current Pharmaceutical Design Mechanisms of Tubulin Binding Ligands to Target Cancer Cells: Updates on their Therapeutic Potential and Clinical Trials
Current Cancer Drug Targets Tumor Invasion and Oxidative Stress: Biomarkers and Therapeutic Strategies
Current Molecular Medicine Bridging Indigenous Knowledge and Scientific Evidence for Pharmacological Studies of <i>Phaleria macrocarpa</i>: A Systematic Review
The Natural Products Journal Protective Effects of Downregulating Estrogen Receptor Alpha Expression in Cervical Cancer
Anti-Cancer Agents in Medicinal Chemistry Role of CD73 in Disease: Promising Prognostic Indicator and Therapeutic Target
Current Medicinal Chemistry